Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights
March 24, 2021 16:01 ET
|
Celyad Oncology SA
No safety concerns or evidence of Graft-versus-Host disease reported from first dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for...
Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call
March 18, 2021 02:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces March 2021 Conference Schedule
March 01, 2021 16:01 ET
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, March 01, 2021 (GLOBE NEWSWIRE) -- Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the...
Celyad Oncology Announces February 2021 Conference Schedule
February 02, 2021 01:00 ET
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)
January 20, 2021 16:05 ET
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium
January 18, 2021 01:00 ET
|
Celyad Oncology SE
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively Tumor burden decrease observed in eight of 15...
Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
January 11, 2021 16:01 ET
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital
January 07, 2021 01:00 ET
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Celyad Oncology Announces January 2021 Conference Schedule
January 05, 2021 01:00 ET
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC
December 15, 2020 16:01 ET
|
Celyad SA
Preliminary data from the expansion cohort are expected during first half 2021 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a...